HOOKIPA Pharma Inc. (HOOK) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

HOOKIPA Pharma Inc. (HOOK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.86

0.08 (4.49%)

At close: Jan 14, 2025, 3:59 PM

1.87

0.54%

After-hours Jan 14, 2025, 04:02 PM EST

undefined% (undefined)

Bid	1.61
Market Cap	17.96M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.67
PE Ratio (ttm)	-0.51
Forward PE	n/a
Analyst	Hold

Ask	1.9
Volume	226,438
Avg. Volume (20D)	122,480
Open	1.81
Previous Close	1.78
Day's Range	1.72 - 1.91
52-Week Range	1.72 - 10.50
Beta	undefined

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-2...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 18, 2019

Employees 151

Stock Exchange NASDAQ

Ticker Symbol HOOK

Website https://www.hookipapharma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for HOOK stock is "Hold." The 12-month stock price forecast is $4.5, which is an increase of 141.94% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

HOOKIPA Pharma Inc. is scheduled to release its earnings on Mar 21, 2025, before market opens.
Analysts project revenue of $6.25M, reflecting a -15.62% YoY shrinking and earnings per share of -1.41, making a -35.91% decrease YoY.

Why Price Moved

6 months ago · Source

-9.38%

HOOKIPA Pharma shares are trading lower after the ... Unlock content with Pro Subscription

News

1 week ago · proactiveinvestors.co.uk

Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with Poolbeg Pharma PLC (AIM:POLB). Gilead, which holds just un...